PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings

Froehner, Michael; Toma, Marieta; Zöphel, Klaus; Laniado, Michael; Wirth, Manfred P.

doi:10.1155/2017/1654231

Cited by 12 publications

(10 citation statements)

References 15 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, PS-MA-avidity is mostly teardrop-or nodular-shapen in lymph node metastases in 50-70% of cases and only rarely (about 1%) in sympathetic trunk uptake (46). Also in benign bone pathologies, where there is a setting of increased vascularity, bone remodeling, and reparative processes like in Paget Syndrome or anemia (47).…”

Section: Basicallymentioning

confidence: 99%

Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?

et al. 2021

View full text Add to dashboard Cite

Section: Basicallymentioning

confidence: 99%

Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?

et al. 2021

View full text Add to dashboard Cite

“…The rapidly expanding role of 68 Ga-labeled PSMA PET/CT in prostate cancer needs careful evaluation as its specificity is limited by some false-positive findings as enumerated in the present article [ Table 1 ]. [ 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 ] Knowledge of these limitations can decrease the potential diagnostic pitfalls and increase the confidence of interpreting physicians.…”

Section: Benign Diseasesmentioning

confidence: 99%

Nonspecific uptake of ⁶⁸Ga-prostate-specific membrane antigen in diseases other than prostate malignancy on positron emission tomography/computed tomography imaging: A pictorial assay and review of literature

et al. 2018

View full text Add to dashboard Cite

68Ga-labeled prostate-specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography imaging (PET/CT) is a rapidly evolving imaging modality for prostate cancer. Many studies have proved its superiority in staging, restaging, and detecting the recurrent prostate cancer. However, case reports describing the incidental tracer uptake in benign and nonprostatic malignancies are also reported in the literature, thus questioning the specificity of the tracer. This pictorial assay illustrates the nonspecific tracer uptake encountered during PSMA PET/CT imaging, knowledge of which can increase the confidence of interpreting physicians and may also open a new path for peptide receptor radionuclide therapy in nonprostatic malignancies.

show abstract

“…Subgroup analysis further supported the superiority of PSMA in all studied clinical settings -primary staging, secondary staging and those with metastatic castrate-resistant prostate cancer. Despite the exquisite sensitivity and specificity of PSMA -a true example of bench-to-bedside translation in molecular science nonspecificity of PSMA seems to arise within certain nonmalignant processes such as Pagets disease [16], as well as certain other cancers including hepatocellular carcinoma, clear-cell kidney cancer and brain tumors [17].…”

Section: Superior Detection Of Bone Metastasesmentioning

confidence: 99%

The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory

et al. 2017

View full text Add to dashboard Cite

Keywords• metastasis • PET • prostate cancer • PSMA • staging Anybody who has spent more than a few hours cutting or rolling a newly laid lawn will be familiar with the blight of dandelions. Catch one before it is seeded and your lawn stands a chance of retaining its pristine lines and surface (Figure 1). But come out one windy evening to find a freshly seeded flower head and all is lost. Even if you pluck it out you can be certain that the tiny seed pods have been carried to all four corners of your lawn and, given a month, will make their presence known. So much for gardening, but cancer surgery is often similar.One of the core principles of radical surgery is accurate staging in the preoperative setting. For most cancers, it is essential to confirm that the tumor is localized -that is, has not yet seeded -such that radical resection can reasonably be expected to achieve a cure [1]. In prostate cancer, various imaging methods have been employed to provide this information, with European Guidelines currently recommending MRI for local staging and CT/bone scan for exclusion of distant metastases for those with intermediate or high-risk disease [2]. However, it is generally accepted that CT/bone scan has low sensitivity and specificity for detection of metastatic disease, with small foci often missed, or conversely nonspecific lesions being detected such as degenerative bone disease or reactive inflammatory changes in the lymph nodes. This being the case, many men with 'localized disease' deemed to be candidates for radical surgery over the past few decades are likely, in fact, to have had small volume or micrometastatic disease. Although it is hard to tease out which subset of men undergoing surgery are in this group, they form part of a cohort in whom we have seen excellent oncological PSMA-PET is changing how we stage prostate cancer, both in the primary setting and with relapse after treatment. It allows us to identify lesions in the bones and lymph nodes that were not previously visible on conventional imaging with bone scan and CT/MRI. In this Special Report we review the 'state of the art' for PSMA imaging and discuss the implications for treatment decisions in prostate cancer. We liken early high risk or metastatic prostate to a common phytological problem: the dandelion. In this analogous situation, we consider the additional evidence needed for us to start plucking out the original dandelion and for us to focus attention on killing the seeded weeds that are identifiable elsewhere in the lawn.

show abstract

PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings

Cited by 12 publications

References 15 publications

Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?

Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?

Nonspecific uptake of ⁶⁸Ga-prostate-specific membrane antigen in diseases other than prostate malignancy on positron emission tomography/computed tomography imaging: A pictorial assay and review of literature

The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory

Contact Info

Product

Resources

About

PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings

Cited by 12 publications

References 15 publications

Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?

Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?

Nonspecific uptake of 68Ga-prostate-specific membrane antigen in diseases other than prostate malignancy on positron emission tomography/computed tomography imaging: A pictorial assay and review of literature

The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory

Contact Info

Product

Resources

About

Nonspecific uptake of ⁶⁸Ga-prostate-specific membrane antigen in diseases other than prostate malignancy on positron emission tomography/computed tomography imaging: A pictorial assay and review of literature